NCT02152254
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Not Applicable
Drug Category: Chemotherapy, Endocrine (Hormone Therapy, Immunotherapy, Misc Inhibitor, Serine-Threonine Kinase Inhibitor, Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Other
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases:
Additional Notes:
Exclusions:
https://clinicaltrials.gov/show/NCT02152254